These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

667 related articles for article (PubMed ID: 33121714)

  • 1. Effects of Canagliflozin on Amino-Terminal Pro-B-Type Natriuretic Peptide: Implications for Cardiovascular Risk Reduction.
    Januzzi JL; Xu J; Li J; Shaw W; Oh R; Pfeifer M; Butler J; Sattar N; Mahaffey KW; Neal B; Hansen MK
    J Am Coll Cardiol; 2020 Nov; 76(18):2076-2085. PubMed ID: 33121714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of canagliflozin on N-terminal pro-brain natriuretic peptide in patients with type 2 diabetes and chronic heart failure according to baseline use of glucose-lowering agents.
    Tanaka A; Toyoda S; Imai T; Shiina K; Tomiyama H; Matsuzawa Y; Okumura T; Kanzaki Y; Onishi K; Kiyosue A; Nishino M; Sakata Y; Node K;
    Cardiovasc Diabetol; 2021 Sep; 20(1):175. PubMed ID: 34479543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of canagliflozin on NT-proBNP stratified by left ventricular diastolic function in patients with type 2 diabetes and chronic heart failure: a sub analysis of the CANDLE trial.
    Kusunose K; Imai T; Tanaka A; Dohi K; Shiina K; Yamada T; Kida K; Eguchi K; Teragawa H; Takeishi Y; Ohte N; Yamada H; Sata M; Node K;
    Cardiovasc Diabetol; 2021 Sep; 20(1):186. PubMed ID: 34521417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of new-onset heart failure in patients with type 2 diabetes derived from ALTITUDE and CANVAS.
    Said F; Arnott C; Voors AA; Heerspink HJL; Ter Maaten JM
    Diabetes Obes Metab; 2024 Jul; 26(7):2741-2751. PubMed ID: 38584567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes.
    Januzzi JL; Butler J; Jarolim P; Sattar N; Vijapurkar U; Desai M; Davies MJ
    J Am Coll Cardiol; 2017 Aug; 70(6):704-712. PubMed ID: 28619659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How should we monitor the cardiovascular benefit of sodium-glucose cotransporter 2 inhibition?
    Tanaka A; Node K
    Cardiovasc Diabetol; 2020 Dec; 19(1):206. PubMed ID: 33287812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program.
    Rådholm K; Figtree G; Perkovic V; Solomon SD; Mahaffey KW; de Zeeuw D; Fulcher G; Barrett TD; Shaw W; Desai M; Matthews DR; Neal B
    Circulation; 2018 Jul; 138(5):458-468. PubMed ID: 29526832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium-glucose co-transporter 2 inhibitor therapy in DECLARE-TIMI 58.
    Zelniker TA; Morrow DA; Mosenzon O; Goodrich EL; Jarolim P; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding J; Bode C; Lewis BS; Gause-Nilsson I; Langkilde AM; Fredriksson M; Raz I; Sabatine MS; Wiviott SD
    Eur J Heart Fail; 2021 Jun; 23(6):1026-1036. PubMed ID: 33269486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study).
    Mahaffey KW; Neal B; Perkovic V; de Zeeuw D; Fulcher G; Erondu N; Shaw W; Fabbrini E; Sun T; Li Q; Desai M; Matthews DR;
    Circulation; 2018 Jan; 137(4):323-334. PubMed ID: 29133604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease.
    Bibbins-Domingo K; Gupta R; Na B; Wu AH; Schiller NB; Whooley MA
    JAMA; 2007 Jan; 297(2):169-76. PubMed ID: 17213400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria.
    Sarraju A; Bakris G; Cannon CP; Cherney D; Damaraju CV; Figtree GA; Gogate J; Greene T; Heerspink HJL; Januzzi JL; Neal B; Jardine MJ; Blais J; Kosiborod M; Levin A; Lingvay I; Weir MR; Perkovic V; Mahaffey KW
    J Am Coll Cardiol; 2022 Nov; 80(18):1721-1731. PubMed ID: 36302584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial.
    Sen T; Li J; Neuen BL; Neal B; Arnott C; Parikh CR; Coca SG; Perkovic V; Mahaffey KW; Yavin Y; Rosenthal N; Hansen MK; Heerspink HJL
    Diabetologia; 2021 Oct; 64(10):2147-2158. PubMed ID: 34415356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minimally elevated cardiac troponin T and elevated N-terminal pro-B-type natriuretic peptide predict mortality in older adults: results from the Rancho Bernardo Study.
    Daniels LB; Laughlin GA; Clopton P; Maisel AS; Barrett-Connor E
    J Am Coll Cardiol; 2008 Aug; 52(6):450-9. PubMed ID: 18672166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamic cardiovascular risk assessment in elderly people. The role of repeated N-terminal pro-B-type natriuretic peptide testing.
    deFilippi CR; Christenson RH; Gottdiener JS; Kop WJ; Seliger SL
    J Am Coll Cardiol; 2010 Feb; 55(5):441-50. PubMed ID: 20117457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes: Vericiguat Heart Failure With Reduced Ejection Fraction Study.
    Ezekowitz JA; O'Connor CM; Troughton RW; Alemayehu WG; Westerhout CM; Voors AA; Butler J; Lam CSP; Ponikowski P; Emdin M; Patel MJ; Pieske B; Roessig L; Hernandez AF; Armstrong PW
    JACC Heart Fail; 2020 Nov; 8(11):931-939. PubMed ID: 33039447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults.
    Kistorp C; Raymond I; Pedersen F; Gustafsson F; Faber J; Hildebrandt P
    JAMA; 2005 Apr; 293(13):1609-16. PubMed ID: 15811980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials.
    Perkovic V; de Zeeuw D; Mahaffey KW; Fulcher G; Erondu N; Shaw W; Barrett TD; Weidner-Wells M; Deng H; Matthews DR; Neal B
    Lancet Diabetes Endocrinol; 2018 Sep; 6(9):691-704. PubMed ID: 29937267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced Trial.
    Januzzi JL; Zannad F; Anker SD; Butler J; Filippatos G; Pocock SJ; Ferreira JP; Sattar N; Verma S; Vedin O; Schnee J; Iwata T; Cotton D; Packer M;
    J Am Coll Cardiol; 2021 Sep; 78(13):1321-1332. PubMed ID: 34556318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure.
    Zile MR; Claggett BL; Prescott MF; McMurray JJ; Packer M; Rouleau JL; Swedberg K; Desai AS; Gong J; Shi VC; Solomon SD
    J Am Coll Cardiol; 2016 Dec; 68(22):2425-2436. PubMed ID: 27908347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical profile and prognostic significance of natriuretic peptide trajectory following hospitalization for worsening chronic heart failure: findings from the ASTRONAUT trial.
    Greene SJ; Maggioni AP; Fonarow GC; Solomon SD; Böhm M; Kandra A; Prescott MF; Reimund B; Hua TA; Lesogor A; Zannad F; Gheorghiade M;
    Eur J Heart Fail; 2015 Jan; 17(1):98-108. PubMed ID: 25597870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.